Table 1.
Baseline demographics and clinical characteristics.
| Characteristics | Total n = 59 |
Cohort A n = 31 |
Cohort B n = 28 |
|---|---|---|---|
| Age, years | |||
| Median | 56.3 | 53.4 | 56.6 |
| Min–Max | 24–72 | 32–72 | 24–72 |
| Sex | |||
| Male | 48 (81.4) | 27 (87.1) | 21 (75) |
| Weight, kg | |||
| <60 | 22 (37.3) | 7 (22.6) | 15 (53.6) |
| ≥60 | 37 (62.7) | 24 (77.4) | 13 (46.4) |
| ECOG PS score | |||
| 0 | 31 (52.5) | 22 (71) | 9 (32.1) |
| 1 | 28 (47.5) | 9 (29) | 19 (67.9) |
| Child–Pugh class | |||
| A5 | 49 (83.1) | 27 (87.1) | 22 (78.6) |
| A6 | 10 (16.9) | 4 (12.9) | 6 (21.4) |
| HCC etiology | |||
| HBV | 54 (91.5) | 30 (96.8) | 24 (85.7) |
| HCV | 0 | 0 | 0 |
| Other | 5 (8.5) | 1 (3.2) | 4 (14.3) |
| BCLC staging | |||
| B | 21 (35.6) | 14 (45.2) | 7 (25) |
| C | 38 (64.4) | 17 (54.8) | 21 (75) |
| Extent of disease | |||
| Macrovascular invasion | 6 (10.2) | 0 | 6 (21.4) |
| Extrahepatic metastases | 32 (54.2) | 17 (54.8) | 15 (53.6) |
| AFP, μg/L | |||
| <400 | 43 (72.9) | 23 (74.2) | 20 (71.4) |
| ≥400 | 16 (27.1) | 8 (25.8) | 8 (28.6) |
| PD-L1 status | |||
| TC/IC ≥ 1% | 27 (45.8) | 14 (45.2) | 13 (46.4) |
| TC/IC < 1% | 27 (45.8) | 13 (41.9) | 14 (50.0) |
| Unknown | 2 (3.4) | 2 (6.5) | 0 |
| Missing | 3 (5.1) | 2 (6.5) | 1 (3.6) |
| Received locoregional therapy | |||
| Yes | 41 (69.5) | 23 (74.2) | 18 (64.3) |
| Percutaneous hepatic arterial chemoembolization | 35 (59.3) | 18 (58.1) | 17 (60.7) |
| Ablation | 13 (22) | 11 (35.5) | 2 (7.1) |
| Radiotherapy | 1 (1.7) | 1 (3.2) | 0 |
| Other | 1 (1.7) | 0 | 1 (3.6) |
| Received surgery | |||
| Yes | 33 (55.9) | 19 (61.3) | 14 (50) |
| No | 26 (44.1) | 12 (38.7) | 14 (50) |
Data are No. (%) unless otherwise indicated.
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; TC, tumor cell; IC, immune cell.